PIK-75_COA_25667_MedChemExpress
3_种常用碳青霉烯类抗生素血药浓度UPLC-MS
3种常用碳青霉烯类抗生素血药浓度UPLC-MS/MS检测方法的建立Δ秦怡1＊，张瑞霞2，吕雅瑶2，翁莉莉1，张弋2 #（1.天津医科大学一中心临床学院，天津 300192；2.天津市第一中心医院药学部，天津 300192）中图分类号 R917；R978.1文献标志码 A 文章编号 1001-0408（2024）03-0343-05DOI 10.6039/j.issn.1001-0408.2024.03.14摘要目的建立3种临床常用碳青霉烯类抗生素——厄他培南（ETP）、亚胺培南（IPM）、美罗培南（MEM）血药浓度检测的超高效液相色谱-质谱联用（UPLC-MS/MS）法。
方法血浆样品经甲醇沉淀蛋白后，以3种抗生素的稳定性同位素（ETP-D4、IPM-D4、MEM-D6）为内标，采用ACQUITY UPLC BEH C18（2.1 mm×50 mm，1.7μm）色谱柱分离；流动相为98%乙腈+2%水+0.1%甲酸和98%水+2%乙腈+0.1%甲酸，梯度洗脱；流速为0.3 mL/min；柱温为40 ℃；采用正离子、多反应监测模式进行扫描分析。
结果该方法专属性良好，在ETP、IPM、MEM 0.2～200、0.1～100、0.1～100μg/mL范围内线性良好（r2≥0.993），批内、批间精密度和准确度良好（RE均≤5.14%，RSD均≤11.15%），基质效应、提取回收率较一致（RSD≤12.99%）。
结论本实验建立了一种可以同时定量ETP、IPM、MEM血药浓度的UPLC-MS/MS法，该方法样品前处理简单、检测时间短、所需样品量少，可满足临床需求。
关键词碳青霉烯类抗生素；超高效液相色谱-质谱联用；血药浓度；厄他培南；亚胺培南；美罗培南Establishment of UPLC-MS/MS method for the determination of plasma concentration of three common carbapenem antibioticsQIN Yi1，ZHANG Ruixia2，LYU Yayao2，WENG Lili1，ZHANG Yi2（1. First Central Clinical College of Tianjin Medical University，Tianjin 300192，China；2. Dept. of Pharmacy，Tianjin First Central Clinical Hospital，Tianjin 300192， China）ABSTRACT OBJECTIVE To establish a UPLC-MS/MS method for the determination of plasma concentration of three carbapenem antibiotics，i.e. ertapenem （ETP），imipenem （IPM）and meropenem （MEM）.METHODS After protein precipitation with methanol，the plasma samples were separated by ACQUITY UPLC BEH C18column （2.1mm×50mm，1.7μm）using stable isotopes of three antibiotics （ETP-D4，IPM-D4，MEM-D6）as the internal standard. The mobile phases were 98%acetonitrile +2% water +0.1%formic acid and 98%water +2%acetonitrile +0.1%formic acid，by gradient elution. The flow rate was 0.3mL/min and the column temperature was 40 ℃. Scanning analysis was performed in the positive ion and multiple reaction monitoring mode. RESULTS The method had good specificity，good linearity （r2≥0.993）in the range of 0.2-200，0.1-100and 0.1-100μg/mL of ETP，IPM and MEM，and good intra-batch and inter-batch precision and accuracy （all RE≤5.14%，all RSD≤11.15%），the matrix effect and extraction recovery were consistent （RSD≤12.99%）. CONCLUSIONS This study establishes the UPLC-MS/MS method to simultaneously quantify the plasma concentration of ETP，IPM and MEM. The method has the advantages of simple pretreatment， short detection time and small sample quantity to meet clinical requirement.KEYWORDS carbapenem antibiotics； UPLC-MS/MS； plasma concentration； ertapenem； imipenem； meropenem碳青霉烯类抗生素具有抗菌谱广、抗菌活性强、耐药率低的特点，已成为治疗重症感染的主要选择。
美国贝克曼库尔特流式细胞分析仪
美国贝克曼库尔特流式细胞分析仪（Beckman coulter cell）产品型号：Cell Lab Quanta SC当前价格：0.00元产品数量：0新旧程度：全新有效期至：0000-00-00所在地：产品简介：仪器简介：T细胞亚群检测的CD45/CD4/CD8/CD3、CD45/CD56/CD19/CD3；阵发性血红蛋白尿（PNH）检测的CD55、CD59；血小板无力症（GT）检测的CD41、CD61等等详细信息仪器简介：T细胞亚群检测的CD45/CD4/CD8/CD3、CD45/CD56/CD19/CD3；阵发性血红蛋白尿（PNH）检测的CD55、CD59；血小板无力症（GT）检测的CD41、CD61等等。
但对于白血病/淋巴瘤免疫分型，国际上迄今为止也没有统一的抗体组合。
在2000年国际细胞分析学会（ISAC）大会上，临床血细胞计数协会组织了一次国际专家会议，以期对检测血液淋巴系统肿瘤所需最少、最有效的单抗数达成共识。
75%与会者一致认为，对于慢性淋巴系统增殖性疾病（CLD）有9种单抗：CD5,CD19,κ,λ,CD3,CD20,CD23,CD10,CD45对初诊来说是最基本的。
淋巴瘤和CLD相似，需要至少12-16种单抗。
对于急性白血病（AL），75%的与会者认为大约13-15种单抗是最基本的：CD10,CD19,CD79a,CD13,CD33,CD34,CD45,CD2,MPO，CD7,CD14,CD3,HLA-DR等，对初步鉴别白血病系列是必需的。
其他一些（CD16,CD56,CDw65,TdT,cyCD3）可能对某些病例有用。
几乎所有的投票者都认为，要对急性白血病完善分类所需单抗的恰当数量平均为20-24种。
但这些抗体之间组合也是一大难题，目前也无统一规定（如表二）。
大会多数发言者(11/13)指出，对已确诊病人的监护和分期来说，仅需较少单抗。
抗体的质量控制是实验的关键环节。
抗体的质量包括其特异性、灵敏度、精密度。
血清C_肽与糖化血红蛋白联合检验在糖尿病临床诊断中的效果分析
· 医学检验 ·糖尿病新世界 2023年4月糖尿病新世界 DIABETES NEW WORLD血清C 肽与糖化血红蛋白联合检验在糖尿病临床诊断中的效果分析郑梅淋，田萍萍，钟秋蓉厦门市海沧医院检验科，福建厦门 361000[摘要] 目的 分析糖尿病临床诊断中应用血清C 肽联合糖化血红蛋白检验的效果。
方法 选取厦门市海沧医院2020年1月—2021年12月收治的200例疑似糖尿病患者为研究对象，将口服葡萄糖耐量试验作为诊断金标准，分别对患者施以血清C 肽检验和糖化血红蛋白检验，比较两组的血清C 肽、血清C 肽联合糖化血红蛋白检验结果。
结果 在200例疑似糖尿病患者中，糖耐量试验检查确诊患者180例，占比90.00%，血清C 肽检测下，阳性检出率为98.33%（177例），血清C 肽联合糖化血红蛋白检测下，阳性检出率为86.11%（155例）。
联合检测的灵敏度、特异度、准确率优于单一检测，差异有统计学意义（P <0.05）。
结论 血清C 肽联合糖化血红蛋白检验能够提升糖尿病临床诊断准确性，可为临床诊断提供更为科学的参考依据。
[关键词] 血清C 肽；糖化血红蛋白；糖尿病；诊断；准确度；联合检验[中图分类号] R59 [文献标识码] A [文章编号] 1672-4062（2023）04（b ）-0066-04Effect Analysis of Combined Test of Serum C-peptide and GlycosylatedHemoglobin in Clinical Diagnosis of Diabetes MellitusZHENG Meilin, TIAN Pingping, ZHONG QiurongDepartment of Laboratory Medicine, Xiamen Haicang Hospital, Xiamen, Fujian Province, 361000 China[Abstract ] Objective To analyze the effect of serum C-peptide combined with glycosylated hemoglobin test in the clinical diagnosis of diabetes. Methods We selected 200 patients with suspected diabetes who were admitted to Xia‐men Haicang Hospital from January 2020 to December 2021 as the research object, and took the oral glucose toler‐ance test as the diagnostic gold standard. Serum C-peptide test and Glycated hemoglobin test were performed on thepatients, and the results of serum C-peptide, serum C-peptide and Glycated hemoglobin test were compared betweenthe two groups. Results Among 200 suspected diabetes patients, 180 patients were diagnosed by Glucose tolerancetest, accounting for 90.00%. The positive detection rate was 98.33% (177 cases) by serum C-peptide test, and 86.11% (155 cases) by serum C-peptide combined with Glycated hemoglobin test. The sensitivity, specificity, and accuracy of combined detection were better than those of single detection, and the difference was statistically significant (P <0.05).Conclusion Serum C-peptide combined with Glycated hemoglobin test can improve the accuracy of clinical diagnosis of diabetes and provide more scientific reference for clinical diagnosis.[Key words ] Serum C-peptide; Glycosylated hemoglobin; Diabetes; Diagnosis; Accuracy; Combined test糖尿病是常见的慢性代谢性疾病，主要因为胰岛素代谢紊乱而引起的代谢性疾病，按照疾病成因，可分成1型糖尿病和2型糖尿病两种类型。
紫杉醇注射液
禁忌症
对本品或其他用聚氧乙基代蓖麻油配制的药
物过敏者。
白细胞低于1.5109/L严重骨髓抑制者。 怀孕和哺乳妇女。
不良反应
消化道反应 食欲减退 恶心呕吐 腹泻
口腔炎 肌肉痛、无力 过敏反应 指趾麻木
骨髓抑制 Hb下降 WBC下降 Plt下降
脱发 毛囊炎 发热 肝功损伤
预处理方法
地塞米松：20mg口服，用泰瑞德前12小时、 6小时各一次
25~32%
40.0%
3 胃癌 Cancer Research
（Ⅱ期， and
27%
46.0
多剂量给 Treatment.2004,1
Thank you!
苯海拉明：50mg 肌注或口服,用泰瑞德前 30~60分钟
西咪替丁：300mg iv,用泰瑞德前30分钟
临床用法
将紫杉醇用生理盐水、5%葡萄糖或5%葡萄糖生
理盐水稀释成0.3~1.2mg/ml溶液。
紫杉醇
剂量及途径
时间
单药 联合用药
135-200mg/m2 IV 135-175mg/m2 IV
紫杉醇概述
来源：紫杉醇（Paclitaxel）属三环二帖类化合物，
是从红豆杉属植物中分离纯化得到的天然抗肿瘤药 物。
化学性质：水溶性差
历程：1992年—1994年FDA正式批准紫杉醇用于治
疗，并于1993年10月美国上市（国外）；1995年国内 开发成功二类新药紫杉醇，于2008年抗肿瘤药物中 排名第二位（国内）。
商品名
剂型
泰素 注射剂
安泰素 注射剂
紫素 注射剂
福王 注射剂
泰瑞德 注射剂
规格
生产企业 零售价
30mg×5ml(支） 百时美施贵宝 1527元
高效液相色谱-质谱联用法检查止喘灵胶囊中非法添加的醋酸泼尼松和茶碱
高效液 相色谱 一质谱联用法检查 止喘灵胶囊中非法添加 的醋酸泼尼松和茶碱
王 戈， 赵培敬
４ ７ ３ ０ ６ １ ） （ 河 南省 南阳市食 品药 品检验 所 ， 河南 南阳
摘要 ： 目 的 采 用 高 效 液 相 色谱 一质 谱 联 用技 术 ， 检 查止喘灵胶 囊中非法添加 的醋酸泼尼松和茶碱 。 方 法 色谱 柱 为 Ｓ ｈ ｉ ｍ ａ ｄ ｚ ｕ ｓ ｈ ｉ ｍ— ｐ ａ ｃ ｋ Ｖ Ｐ— Ｏ Ｄ Ｓ柱 （ ２ ５ ０ ｍｍ ｘ ４ ． ６ ｍ ｍ， ５ ｍ） ， ０ ． ０ ２ ｍ ｏ ｌ ／ Ｌ乙酸铵 一 ０ ． １ ％ 冰醋 酸 水溶 液 ： 乙腈 （ ７ １ ： ２ ９ ） 为 流动 相 ， 流速 为 １ ． ０ ｍ Ｌ ／ ｍｉ ｎ ； Ａ ｇ ｉ ｌ ｅ ｎ ｔ ６ ３ １ ０型 离子 阱质 谱仪 ， 电喷 雾 离子源 （ Ｅ Ｓ Ｉ ） ， 雾化 气压 力为 ５ ０ ｐ ｓ ｉ ， 干燥 气温 度 为 ３ ８ ０ ℃， 流速 为 ９ ． ５ ｍＬ ／ ｍ ｉ ｎ ， 毛 细管 电压 为 ３ ５ ０ ０ Ｖ， 扫 描 范 围为 １ ０ ０～ ５ ０ ０ｍ／ ｚ ， 检 测方式为正、 负模 式 一 级 、 二 级 同时 扫 描 。 结 果 在 高 效 液 相 色谱 、 质谱 中， 样 品 出现 与 醋 酸 泼 尼松 、 茶 碱 成 分 一 致 的 色谱峰 、 质 谱峰 。 结 论 所 用方 法 简 单 可行 ， 结 果 准确 可 靠 ， 可 用于 止 喘 灵胶 囊 中非 法 添加 醋 酸 泼 尼松 、 茶碱 的定 性 鉴 别 。
Ａ ｂ ｓ ｔ ｒ ａ ｃ ｔ ： ０ ｂ ｊ ｅ ｃ ｔ ｉ ｖ ｅ Ｔ ｏ ｅ ｓ ｔ ａ ｂ ｌ ｉ ｓ ｈ ａ Ｈ Ｐ Ｌ Ｃ— ＭＳ ／ ＭＳ ｍ ｅ ｔ ｈ ｏ ｄ ｆ ｏ ｒ ｄ ｅ ｔ ｅ ｃ ｔ ｉ ｎ ｇ ｐ ｒ ｅ ｄ ｎ ｉ ｓ ｏ ｎ ｅ ａ ｃ ｅ ｔ ａ ｔ ｅ ａ ｎ ｄ ｔ ｈ ｅ ｏ ｐ ｈ ｙ ｌ ｌ ｉ ｎ ｅ ｉ ｌ ｌ ｅ ｇ ａ ｌ ｌ ｙ ａ ｄ ｄ ｅ ｄ ｉ ｎ
PIK-75-SDS-MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Oct.-04-2018Print Date:Oct.-04-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :PIK-75Catalog No. :HY-13281CAS No. :372196-77-51.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:PIK-75 Hydrochloride;PIK 75Formula:C16H15BrClN5O4SMolecular Weight:488.74CAS No. :372196-77-54. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2018 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。